Recurrent Glioblastoma Multiforme Treatment Market, by Treatment (Oral Medication, Radiosensitizers, Nitrosoureas Drugs, and Chemotherapy ), by Type (Grade II or Grade III, Grade IV, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Published In : Aug 2020

Code : CMI682

Pages :145

Formats :

Excel and PDF

Industry : Pharmaceutical

Market News

In January 2020, Pfizer launched ‘Zirabev’ in the U.S., which is a bevacizumab biosimilar of Avastin, approved for the treatment of recurrent glioblastoma multiforme. The biosimilar was approved by FDA in June 2019 for the treatment of metastatic or recurrent NSCLC, metastatic colorectal cancer, recurrent glioblastoma multiforme, recurrent/persistent or metastatic cervical cancer, and metastatic renal cell carcinoma

Furthermore, key players in the industry are involved in joint ventures and collaborations to develop and commercialize novel drugs, in order to strengthen their position in the global recurrent glioblastoma multiforme treatment market. For instance, in May 2017, DelMar Pharmaceuticals formalized the collaboration agreement with PRA Health Sciences to conduct phase 3 trials of VAL-083 for the treatment of recurrent GBM. PRA Health Sciences is a contract research organization (CRO) that provides outsourced clinical development services to the pharmaceutical and biotechnology industries.

In November 2019, the U.S. FDA accepted Samsung’s BLA application for SB8 bevacizumab, a biosimilar of Avastin. If this gets approval, this biosimilar will be commercialized in the U.S. market by Merck & Co., Inc., which has also been Samsung’s partner on its biosimilar of infliximab – Renflexis.